Given the important medical need to improve the risk–benefit trade-off of HSCT and CD45-targeting ADC being highly promising to achieve this goal36, we consider that the off-target editing found here constitutes a reasonable safety profile if used for AML. The gene discussed is PTPRC; the disease is acute myeloid leukemia.